Mimma Rizzo

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Venues

Therapeutic advances in urology

Journal of clinical medicine

Oncoimmunology

Nature reviews. Nephrology

Fondazione Salvatore Maugeri Istituto Scientifico di Pavia Via Maugeri

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fondazione Salvatore Maugeri Istituto Scientifico di Pavia Via Maugeri

Italy

Oncologo Medico

Publications

Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, Elena Varotti, Federico Quaini, Nicoletta Campanini, Elena Rapacchi, Roberta Camisa, Paolo Carbognani, Enrico Maria Silini, Michele Rusca, Francesco Leonardi, Umberto Maestroni, Mimma Rizzo, Matteo Brunelli, Sebastiano Buti, Luca Ampollini
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity. Exploration of targeted anti-tumor therapy 4 (4) (2023)
Gaetano Pezzicoli, Francesco Salonne, Vittoria Musci, Federica Ciciriello, Stefania Tommasi, Rosanna Lacalamita, Francesco Alfredo Zito, Sara Antonia Allegretta, Antonio Giovanni Solimando, Mimma Rizzo
Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study. Journal of clinical medicine 12 (24) (2023)
Itske Fraterman, Barbara M Wollersheim, Valentina Tibollo, Savannah Lucia Catherina Glaser, Stephanie Medlock, Ronald Cornet, Matteo Gabetta, Vitali Gisko, Ella Barkan, Nicola di Flora, David Glasspool, Alexandra Kogan, Giordano Lanzola, Roy Leizer, Henk Mallo, Manuel Ottaviano, Mor Peleg, Lonneke V van de Poll-Franse, Nicole Veggiotti, Konrad Śniatała, Szymon Wilk, Enea Parimbelli, Silvana Quaglini, Mimma Rizzo, Laura Deborah Locati, Annelies H Boekhout, Lucia Sacchi, Sofie Wilgenhof
An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial. JMIR research protocols 12 (2023)
Gaetano Pezzicoli, Francesco Salonne, Vittoria Musci, Federica Ciciriello, Stefania Tommasi, Rosanna Lacalamita, Francesco Alfredo Zito, Sara Antonia Allegretta, Antonio Giovanni Solimando, Mimma Rizzo
Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study. Journal of clinical medicine 12 (24) (2023)
Mimma Rizzo, Patrizia Giannatempo, Camillio Porta
Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. Biologics : targets & therapy 15 (2021)
Antonio Russo, Daniele Fanale, Giuseppe Badalamenti, Camillio Porta, Daniel Olive, Ida De Luca, Chiara Brando, Mimma Rizzo, Carlo Messina, Mattia Rediti, Antonio Russo, Viviana Bazan, Juan Lucio Iovanna
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology 9 (1) (2020)
Francesco Massari, Veronica Mollica, Alessandro Rizzo, Laura Cosmai, Mimma Rizzo, Camillio Porta
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert opinion on drug safety 19 (10) (2020)
Camillo Porta, Mimma Rizzo
Immune-based combination therapy for metastatic kidney cancer. Nature reviews. Nephrology 15 (6) (2020)
Camillio Porta, Patrizia Giannatempo, Mimma Rizzo, Giuseppe Lucarelli, Pasquale Ditonno, Michele Battaglia
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. Expert opinion on pharmacotherapy 21 (18) (2020)

Mimma Rizzo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mimma Rizzo